IL13 and asthma: Dupilumab, a human mAb that binds to IL-4Rα, inhibits both IL-4 and IL-13 signaling and reduces asthma exacerbations, decreases oral corticosteroid (OCS) dosage, and improves lung function and symptom control in patients with asthma.6